Polomar Health Services, Inc. (PMHS) stock: key figures, P/E, revenue and dividend
Health Care · United States
Polomar Health Services, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 648,231.00 USD |
| Gross profit | 460,099.00 USD |
| Operating income | -10.55 m USD |
| EBIT | -10.55 m USD |
| Net income | -10.70 m USD |
| Diluted EPS – continuing operations | -0.39 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Polomar Health Services, Inc.
Polomar Health Services, Inc. operates as a retail compounding pharmacy in the United States. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; Tofacitinib, it treats rheumatoid arthritis by inhibiting JAK to reduce inflammation and pain; Semaglutide GLP-1, which regulates blood sugar, appetite, and weight in diabetes management; and compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.
More stocks
- Advanced Biomed Inc. (ADVB)
- REGIONAL HEALTH PROPERTIES, INC (RHEP)
- bioAffinity Technologies, Inc. (BIAF)
- FLYWHEEL ADVANCED TECHNOLOGY, INC. (FWFW)
- Amesite Inc. (AMST)
- Strive, Inc. (ASST)
- VisitIQ Corp. (VIIQ)
- Borqs Technologies, Inc. (BRQSF)
- CXApp Inc. (CXAI)
- Xenetic Biosciences, Inc. (XBIO)
- Silo Pharma, Inc. (SILO)
- MANGOCEUTICALS, INC. (MGRX)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.